Zoom系统连续双重抽吸技术治疗卒中 (ADAPT 2 0)
使用Zoom系统的连续双抽吸技术治疗脑卒中的临床评估(ADAPT 2.0)
This study is designed to evaluate the effectiveness, safety and clinical performance of ADAPT 2.0, first-line aspiration neurothrombectomy with Zoom System with Continuous Dual Aspiration Technique (CDAT).
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Pojai Phattanagosai
- 电话号码:650-740-7703
- 邮箱:pphattanagosai@Imperativecare.com
研究联系人备份
- 姓名:Emma Pham
- 电话号码:408-421-7684
- 邮箱:epham@imperativecare.com
学习地点
-
-
Alabama
-
Huntsville、Alabama、美国、35801
- 招聘中
- Huntsville Hospital
-
接触:
- Farrar Hickey
-
首席研究员:
- R. Dana Tomalty, MD
-
-
California
-
Walnut Creek、California、美国、94598
- 招聘中
- John Muir Health
-
首席研究员:
- Benjamin Yim, MD
-
接触:
- Melenie Aaron
-
-
Florida
-
Tampa、Florida、美国、33606
- 招聘中
- University of South Florida
-
首席研究员:
- Maxim Mokin, MD
-
接触:
- Kilaun Robinson
-
-
Georgia
-
Marietta、Georgia、美国、30060
- 招聘中
- Wellstar Kennestone Hospital
-
接触:
- Autumn Lee
-
首席研究员:
- Ahmad Khaldi, MD
-
-
Louisiana
-
Lafayette、Louisiana、美国、70503
- 招聘中
- Ochsner Clinic Foundation (Lafayette)
-
首席研究员:
- Shail Thanki, MD
-
New Orleans、Louisiana、美国、70121
- 招聘中
- Ochsner Clinic Foundation
-
首席研究员:
- James Milburn, MD
-
接触:
- Jessica Henry
-
-
Maryland
-
Baltimore、Maryland、美国、21201
- 招聘中
- University of Maryland
-
首席研究员:
- Jacob Cherian, MD
-
接触:
- Katie Henry
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55407
- 招聘中
- Allina Health
-
接触:
- Emeryth Beloy
-
首席研究员:
- Collin Torok, MD
-
-
New York
-
Albany、New York、美国、12208
- 招聘中
- Albany Medical College
-
首席研究员:
- Alexandra Paul, MD
-
接触:
- Chelsey Large
-
Buffalo、New York、美国、14203
- 招聘中
- University at Buffalo Neurosurgery
-
首席研究员:
- Jason Davies, MD
-
接触:
- Ellen Carl
-
New York、New York、美国、10065
- 招聘中
- Weill Cornell Medicine
-
接触:
- Hanah Hwang
-
首席研究员:
- Amol Mehta, MD
-
New York、New York、美国、10029
- 招聘中
- Icahn School of Medicine at Mount Sinai
-
接触:
- Kevin Buttet
-
首席研究员:
- Michael T Caton, MD
-
Syracuse、New York、美国、13210
- 招聘中
- SUNY Upstate Medical Center
-
接触:
- Saptarshi Prachi
-
首席研究员:
- Haydn Hoffman, MD
-
The Bronx、New York、美国、10467
- 招聘中
- Montefiore Medical Center
-
接触:
- Genesis Liriano
-
首席研究员:
- Amanda Baker, MD
-
-
Ohio
-
Cincinnati、Ohio、美国、45220
- 招聘中
- TriHealth Good Samaritan Hospital
-
首席研究员:
- Andrew Ringer, MD
-
接触:
- Mehnaaz Ali
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma, Health Science Center
-
首席研究员:
- Hakeem Shakir, MD
-
接触:
- Sanaa Hameed
-
-
South Carolina
-
Greenville、South Carolina、美国、29605
- 招聘中
- Prisma Health - Upstate
-
接触:
- Shawn Manos
-
首席研究员:
- Jan Vargas Machaj, MD
-
-
Tennessee
-
Knoxville、Tennessee、美国、37902
- 招聘中
- Fort Sanders Regional Medical Center
-
接触:
- Cameron Carter
-
首席研究员:
- Robert Hixson, MD
-
Memphis、Tennessee、美国、38120
- 招聘中
- Semmes Murphey Foundation
-
首席研究员:
- Lucas Elijovich, MD
-
接触:
- Wendell Barnett
-
-
Texas
-
Kingwood、Texas、美国、77339
- 招聘中
- HCA Houston Healthcare Kingwood
-
首席研究员:
- Mohamad Ezzeldin, MD
-
接触:
- Swathi Potla
-
San Antonio、Texas、美国、78229
- 招聘中
- Methodist Healthcare System of San Antonio
-
接触:
- Samantha Franklin
-
首席研究员:
- Lee Birnbaum, MD
-
San Antonio、Texas、美国、78229
- 招聘中
- University of Texas Science Health Center at San Antonio
-
首席研究员:
- Justin Mascitelli, MD
-
接触:
- Athena Lazaris-Conner
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- 招聘中
- University of Utah
-
接触:
- Andrew Grandemange
-
首席研究员:
- Robert Rennert, MD
-
-
Virginia
-
Falls Church、Virginia、美国、22042
- 招聘中
- Inova Fairfax Medical Campus
-
接触:
- Lauren Monroe
-
首席研究员:
- James McEachern, MD
-
-
Washington
-
Spokane、Washington、美国、99204
- 招聘中
- Providence Sacred Heart Medical Center and Children's Hospital
-
接触:
- Kyle Kramer
-
首席研究员:
- Christopher Zylak, MD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adult subjects with acute ischemic stroke secondary to large vessel occlusion (LVO) meeting the study eligibility criteria and providing written informed consent.
描述
Inclusion Criteria:
- Subject is ≥ 18 years of age
- Subject or legally authorized representative has provided written informed consent prior to any study-specific procedures and no later than 72 hours after the index procedure
- Pre-stroke mRS 0-2
- Subject is undergoing or has undergone an aspiration thrombectomy using the Zoom System with Continuous Dual Aspiration Technique (CDAT) as the first line device within its intended use
Exclusion Criteria:
- Subjects with a life expectancy of less than 6 months
- Female subject who is known to be pregnant at time of admission
- Any intracranial hemorrhage in the qualifying head CT or MRI
- Presence of tandem internal carotid artery occlusion, multiple occlusion locations (e.g., cavernous ICA and M1, separate M2 occlusions, etc.), or occlusions in multiple territories (e.g., MCA and ACA, bilateral, etc.).
- In the opinion of the Investigator, the patient is not a suitable candidate for intervention with the Zoom System
- Subject is currently enrolled in or planned to be enrolled in any concurrent interventional study that may impact the safety or performance data collected in this study
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
ADAPT 2.0: Zoom System with Continuous Dual Aspiration Technique (CDAT)
The Zoom System is intended to be used as the first-line device and utilized within the FDA-cleared indications for use, consistent with the approved labeling and intended anatomical targets. |
Aspiration neurothrombectomy using Zoom System with Continuous Dual Aspiration Technique (CDAT)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of patients achieving modified Thrombolysis in Cerebral Infarction (mTICI) score of ≥2c at the end of procedure, as adjudicated by independent core-lab
大体时间:End of procedure
|
mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
End of procedure
|
|
Rate of Embolization to New Territory (ENT) on final angiography at the end of the procedure by investigator assessment
大体时间:End of procedure
|
Embolization to New Territory (ENT), defined as the presence of new occlusions on final angiography that occur in vascular territories remote from those effected by index stroke, as assessed by the investigator |
End of procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to achieve mTICI≥2c, defined as groin puncture to investigator assessment for mTICI≥2c
大体时间:Intraprocedural
|
The time from groin puncture to mTICI (modified treatment in cerebral infarction) score ≥ 2c using study device and technique. mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the Zoom POD
大体时间:Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within at least one of the Zoom PODs |
Intraprocedural
|
|
Proportion of cases with clot captured within the Zoom POD connected to the outer aspiration catheter
大体时间:Intraprocedural
|
Proportion of cases with clot ingestion, as evidenced by clot captured within the outer Zoom PODs |
Intraprocedural
|
|
Rate of rescue therapy
大体时间:Intraprocedural
|
Proportion of cases with rescue therapy, defined as unplanned use of another manufacturer's thrombectomy device, angioplasty, or stenting within the target vessel territory to achieve mTICI≥2c. |
Intraprocedural
|
|
Rate of functional independence (mRS 0-2) at 90 days
大体时间:90 days post-procedure
|
Proportion of patients achieving mRS (modified Rankin Scale) ≤2 at 90 days mRS range: 0 to 6; The mRS scale ranges from 0 (no symptoms) to 5 (severe disability), with an additional category of 6 for death; higher score means worse outcome |
90 days post-procedure
|
|
Proportion of patients achieving First Pass Effect (FPE) mTICI ≥2c as adjudicated by independent core-lab
大体时间:Intraprocedural
|
Proportion of cases achieving First Pass Effect (FPE), defined as mTICI ≥2c after the first pass with the study device and technique as adjudicated by independent core-lab mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion. mTICI 0: No antegrade reperfusion; mTICI 1: Antegrade reperfusion past initial occlusion, limited distal filling; mTICI 2a: Antegrade reperfusion of less than half (<50%) of the previously occluded target artery's ischemic territory; mTICI 2b: Antegrade reperfusion of more than half (≥50%) of the previously occluded target artery's ischemic territory; mTICI 2c: Near-complete (90-99%) reperfusion, or filling of all distal branches with slower flow; mTICI 3: Complete antegrade reperfusion of all branches |
Intraprocedural
|
|
Rate of symptomatic intracranial hemorrhage (sICH), as confirmed by imaging and independently adjudicated by medical monitor, at the 24-hour post-procedure
大体时间:24-hour post-procedure
|
Independently adjudicated rate of symptomatic intracranial hemorrhage (sICH) defined as any apparently extravascular blood in the brain or within the cranium confirmed by imaging that is associated with clinical deterioration as defined by an increase of four or more points in the NIHSS at 24 hours compared to the baseline assessment, or that led to death, and was judged to be the predominant cause of a neurologic deterioration or death, per ECASS III criteria |
24-hour post-procedure
|
|
90-day all-cause mortality
大体时间:90 days post-procedure
|
Rate of all-cause mortality through 90 days post-procedure |
90 days post-procedure
|
|
Rate of device-related Serious Adverse Events, independently adjudicated medical monitor
大体时间:Intraprocedural
|
Independently adjudicated rate of Serious Adverse Events related to study device |
Intraprocedural
|
合作者和调查者
调查人员
- 首席研究员:David Fiorella, MD、Stony Brook University Hospital
- 首席研究员:Shahram Majidi, MD、Icahn School of Medicine at Mount Sinai
- 首席研究员:Justin Masciteli, MD、The University of Texas Health Science Center at San Antonio
- 首席研究员:Maxim Mokin, MD、University of South Florida
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.